Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor

NCT00495872 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

204

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: Dasatinib
DRUG: Erlotinib
DRUG: Lapatinib
DRUG: Lenalidomide
DRUG: Sorafenib
DRUG: Sunitinib
DRUG: Valproic Acid

Sponsor

M.D. Anderson Cancer Center